Comprehensive Study Guide for Community-Acquired, Hospital-Acquired, and Ventilator-Associated Pneumonia

Community-Acquired Pneumonia (CAP) Definition and Clinical Manifestations

• Definition: Community-Acquired Pneumonia is defined as an acute infection of the pulmonary parenchyma acquired outside of the hospital setting. High-quality guideline evidence for this diagnosis assumes the presence of a compatible clinical syndrome paired with radiographic confirmation of a new pulmonary infiltrate.

• Clinical Symptoms and Signs: Patients typically present with a variety of respiratory and systemic symptoms, including:

  • Cough, which may or may not be productive of sputum.
  • Dyspnea (shortness of breath).
  • Fever and chills.
  • Pleuritic chest pain (pain associated with breathing).
  • Fatigue and general malaise.
  • Physical exam signs may include tachypnea (increased respiratory rate), hypoxemia (low oxygen levels), and the presence of crackles upon auscultation of the lungs.

CAP Pathogen Classification and Resistance Patterns

• Typical Bacterial Pathogens: The most frequent organisms responsible for CAP include:

  • Streptococcus pneumoniae (identified as a key pathogen).
  • Haemophilus influenzae.
  • Moraxella catarrhalis.
  • Methicillin-susceptible Staphylococcus aureus (MSSA).

• Atypical Pathogens: These organisms often require different diagnostic and therapeutic approaches:

  • Mycoplasma pneumoniae.
  • Chlamydia pneumoniae.
  • Legionella species.

• Resistant Pathogens: Methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa are not routinely covered unless validated risk factors are present.

• Viral Infections: Viruses are known to coexist with bacterial pathogens in cases of CAP.

Diagnostic Criteria and Severity Assessment for CAP

• Diagnosis: Confirmation of CAP requires both compatible symptoms/physical signs and evidence of a new infiltrate on chest imaging. Procalcitonin (PCT) levels should not be used as the sole factor to withhold initial antibiotic therapy if the clinical picture suggests pneumonia.

• Site of Care Determination: The Pneumonia Severity Index (PSI) is preferred over other scoring systems to guide the decision of whether a patient should be treated as an outpatient or inpatient, though this must be combined with clinical judgment.

• Severe CAP Criteria: Defined as the presence of at least one major criterion or at least three minor criteria.

  • Major Criteria:
    1. Septic shock requiring the administration of vasopressors.
    2. Respiratory failure requiring mechanical ventilation.
  • Minor Criteria:
    • Respiratory Rate (RR) $\ge 30 \text{ breaths/min}$.
    • $PaO_2/FiO_2 \le 250$.
    • Presence of multilobar infiltrates on imaging.
    • Confusion or altered mental status.
    • Blood Urea Nitrogen (BUN) $\ge 20 \text{ mg/dL}$.
    • White Blood Cell (WBC) count $< 4,000 \text{ cells/mm}^3$.
    • Platelet count $< 100,000 / \text{mm}^3$.
    • Core temperature $< 36^\circ \text{C}$ (hypothermia).
    • Hypotension requiring aggressive fluid resuscitation.

• Microbiologic Testing/Cultures:

  • Sputum and blood cultures are indicated for patients with severe CAP, those receiving empiric MRSA or Pseudomonas coverage, those with prior history of these pathogens, or those hospitalized with IV antibiotics within the previous $90 \text{ d}$.
  • Legionella urine antigen testing is recommended for severe CAP cases or in the context of specific outbreak/travel risks.

Outpatient Management of CAP

• Patients Without Comorbidities: Recommended regimens include:

  • Amoxicillin $1 \text{ g PO TID}$.
  • Doxycycline $100 \text{ mg PO BID}$.
  • Azithromycin is only appropriate as monotherapy if local rates of pneumococcal macrolide resistance are $< 25\%$.

• Patients With Comorbidities: Recommended regimens include:

  • Amoxicillin/clavulanate $875/125 \text{ mg PO BID}$ OR a cephalosporin (Cefpodoxime $200 \text{ mg BID}$ or Cefuroxime $500 \text{ mg BID}$) PLUS a macrolide (azithromycin) or doxycycline.
  • Respiratory fluoroquinolone monotherapy: Levofloxacin $750 \text{ mg daily}$ or Moxifloxacin $400 \text{ mg daily}$.

Inpatient Management and Pathogen Coverage for CAP

• Nonsevere Inpatient:

  • Combination therapy of a beta-lactam (e.g., Ceftriaxone $1\text{--}2 \text{ g IV q24h}$) plus a macrolide (Azithromycin $500 \text{ mg daily}$).
  • Alternative: Monotherapy with a respiratory fluoroquinolone.

• Severe Inpatient:

  • Beta-lactam plus a macrolide.
  • Beta-lactam plus a respiratory fluoroquinolone.

• Target Coverage Details:

  • Beta-lactams: Target typical bacteria but provide no coverage for atypical organisms.
  • Azithromycin and Doxycycline: Target atypical pathogens.
  • Respiratory Fluoroquinolones: Provide broad coverage for both typical and atypical bacteria.
  • MRSA Specifics: Use Vancomycin or Linezolid.
  • Pseudomonas Specifics: Use Piperacillin/tazobactam, Cefepime, Ceftazidime, Meropenem, Imipenem, or Aztreonam.

Medication Side Effects and Monitoring Parameters

• Beta-lactams: Monitored for allergic reactions, diarrhea, or Clostridioides difficile infection. Dosages must be adjusted for renal function. Cefepime specifically carries a risk of neurotoxicity if it accumulates due to renal impairment.

• Macrolides: Associated with gastrointestinal (GI) upset, QTc interval prolongation, and various drug-drug interactions.

• Fluoroquinolones: Associated with QTc prolongation, tendon injury/rupture, central nervous system (CNS) effects, and dysglycemia.

• Vancomycin: Monitored for nephrotoxicity and infusion-related reactions. Monitoring includes regular assessment of renal function and drug levels or exposure.

• Linezolid: Monitored for thrombocytopenia and myelosuppression. A Complete Blood Count (CBC) is required. Physicians must watch for serotonergic interactions.

• General Efficacy Monitoring: Success is measured by serial assessment of temperature, Heart Rate (HR), Respiratory Rate (RR), Blood Pressure (BP), oxygen saturation/requirements, WBC count, improvements in cough/dyspnea, oral intake capacity, and mental status.

CAP Management Plan, Contingency, and Follow-up

• Standardized Plan:

  1. Confirm diagnosis and determine appropriate site of care and severity.
  2. Collect indicated cultures and diagnostic tests before starting antibiotics if possible.
  3. Initiate empiric therapy promptly.
  4. Review microbiology results and clinical status at $48\text{--}72 \text{ h}$.
  5. Narrow antibiotic spectrum and transition from IV to PO when the patient is stable and can absorb oral medications.

• Contingency for Failure to Improve: If the patient worsens or fails to improve within $48\text{--}72 \text{ h}$, clinicians must reassess the diagnosis and confirm proper dosing and adherence. Evaluation should include looking for empyema, lung abscess, obstruction, or other infection sources. Escalate coverage for MRSA or Pseudomonas only when supported by microbiologic data or high-risk findings.

• Follow-up and Duration: Treatment should continue until the patient is clinically stable and has received a total of $\ge 5 \text{ days}$ of therapy. Routine follow-up chest imaging is not necessary if symptoms resolve. De-escalation of MRSA or Pseudomonas coverage should occur around $48 \text{ h}$ if cultures remain negative.

Hospital-Acquired Pneumonia (HAP): Definition, Symptoms, and Pathogens

• Definition: Pneumonia that occurs $\ge 48 \text{ h}$ after hospital admission and was not incubating at the time of admission. It is specifically not associated with mechanical ventilation.

• Symptoms and Signs: A new or progressive infiltrate on imaging plus infectious evidence such as new fever, purulent sputum/secretions, leukocytosis/leukopenia, or declining respiratory status/oxygenation.

• Common HAP Pathogens: Organisms include MSSA, MRSA, Pseudomonas aeruginosa, and other aerobic Gram-negative rods (GNR) or Enterobacterales. Local ecology and antibiograms should guide selection.

HAP Diagnosis and Empiric Treatment Strategies

• Diagnosis: There is no single gold standard for diagnosis. Clinicians should obtain noninvasive respiratory cultures and blood cultures. Decisions to start antibiotics should be based on clinical criteria rather than Procalcitonin (PCT), C-reactive protein (CRP), or the Clinical Pulmonary Infection Score (CPIS) alone.

• Empiric Therapy for All Cases: Every HAP regimen must cover S. aureus and Gram-negative rods including Pseudomonas.

• Low MRSA and Mortality Risk: Use a single agent with MSSA and antipseudomonal activity:

  • Piperacillin/tazobactam $4.5 \text{ g IV q6h}$.
  • Cefepime $2 \text{ g IV q8h}$.
  • Levofloxacin $750 \text{ mg IV q24h}$.
  • Imipenem $500 \text{ mg IV q6h}$ or Meropenem $1 \text{ g IV q8h}$.

• MRSA and High Mortality Factors:

  • Add Vancomycin or Linezolid if MRSA risks are present (prior IV antibiotics within $90 \text{ d}$ or unit MRSA prevalence $> 20\%$).
  • High mortality risk is defined as the need for ventilatory support due to HAP or the presence of septic shock. Two antipseudomonal classes are required if prior IV antibiotics were used within $90 \text{ d}$ or if there is a high risk of mortality.

• Pathogen-Directed Therapy: For proven MSSA, Oxacillin, Nafcillin, or Cefazolin are the preferred agents.

Ventilator-Associated Pneumonia (VAP): Definition and Diagnosis

• Definition: Pneumonia that develops $> 48 \text{ h}$ after endotracheal intubation.

• Signs/Symptoms: New or progressive infiltrate, fever, purulent endotracheal secretions, leukocytosis or leukopenia, and increased ventilator requirements or declining oxygenation.

• Diagnostic Sampling: Noninvasive endotracheal aspiration with semiquantitative culture is preferred. If invasive quantitative cultures are used and result below diagnostic thresholds, antibiotics may be withheld if clinically appropriate.

VAP Pathogens and Multidrug-Resistance (MDR) Risk Factors

• Pathogens: MSSA, MRSA, P. aeruginosa, and other aerobic Gram-negative rods (GNR).

• MDR Risk Factors for VAP:

  • Intravenous antibiotic use within the previous $90 \text{ d}$.
  • Septic shock present at the onset of VAP.
  • Acute Respiratory Distress Syndrome (ARDS) preceding the VAP diagnosis.
  • Hospitalization for $\ge 5 \text{ days}$ prior to VAP onset.
  • Acute renal replacement therapy (RRT) required before VAP onset.

VAP Empiric Treatment and Clinical Management

• Empiric Regimen: Must cover S. aureus, Pseudomonas, and GNR.

• MRSA Coverage: Add Vancomycin or Linezolid if antimicrobial-resistance risk exists, or if the unit MRSA prevalence is $> 10\text{--}20\%$.

• Antipseudomonal Strategy: Two classes are used if there is an MDR risk, $> 10\%$ GNR resistance to a proposed monotherapy, or the patient has bronchiectasis/cystic fibrosis. Otherwise, one agent suffices.

• Agent Selection: Common beta-lactam and fluoroquinolone doses match those of HAP. Aminoglycosides and colistin should be avoided if adequate alternatives exist. Inhaled antibiotics may be used as a last resort for highly resistant GNR infections.

Clinical Monitoring, Follow-up, and Drug Pearls

• Monitoring: Continuous assessment of oxygenation, ventilator requirements, sputum, fever, WBC, hemodynamics, and renal function is necessary.

• Duration of Therapy: For most cases of HAP and VAP, a $7 \text{ d}$ course of antibiotics is recommended, though this should be adjusted based on clinical, radiologic, and lab response.

• Specific Drug Pearls:

  • Resistance Clue: The strongest predictor of a resistant pathogen is prior respiratory isolation/infection with MRSA or Pseudomonas.
  • HCAP: The Health Care-Associated Pneumonia (HCAP) category has been abandoned.
  • Aspiration: Anaerobic coverage should not be routinely added for aspiration unless a lung abscess or empyema is suspected.
  • Steroids: Corticosteroids are not routine for CAP but may be used in refractory septic shock.
  • Influenza: If an inpatient with CAP tests positive for influenza, treat with an anti-influenza agent like Oseltamivir.
  • VAP/Tracheobronchitis: Ventilator-associated tracheobronchitis generally does not require antibiotic treatment.

• Guidelines Referenced:

  • 2019 Adult CAP Guideline (American Thoracic Society/Infectious Diseases Society of America).
  • 2016 HAP/VAP Guideline (ATS/IDSA).